Table 1.
Phenotypic and genetic characteristics of the bacterial strains used in this work
| Straina | β-Lactamase/class 1 integron cassette array | MIC (μg/ml)b |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMK | GEN | CEF | CRO | CAZ | FEP | ATM | IPM | MEM | ETP | CIP | TZP | AMC | RIF | PMB | TGC | ||
| KPN106 | blaKPC-2, blaCTX-M-2, blaSHV-11, blaTEM-1, arr-8, dhfrIIIc | 16 | 32 | ≥256 | ≥64 | ≥64 | 8 | 128 | ≥16 | ≥16 | ≥8 | ≥8 | ≥256 | 128 | ≥8 | 0,25 | 1 |
| TF106 | blaKPC-2, arr-8, dhfrIIIc | 16 | 0.25 | 64 | >64 | >64 | 8 | 128 | >16 | >16 | >8 | 0.25 | >128 | 32 | 0.25 | 0.25 | 0.03 |
| DH5α | None | 0.12 | 0.25 | 8 | 0.06 | 0.5 | 0.5 | 0.5 | 0.12 | <0.015 | 0.003 | 0.004 | <2 | <1 | 0.03 | <0.12 | 0.06 |
a
KPN106, K. oxytoca isolate; TF106, E. coli transformant KPN106; DH5α, E. coli recipient strain.
b
AMK, amikacin; GEN, gentamicin; CEF, cephalothin; CRO, ceftriaxone; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; IPM, imipenem; MEM, meropenem; ETP, ertapenem; CIP, ciprofloxacin; TZP, piperacillin-tazobactam; AMC, amoxicillin-clavulanate; RIF, rifampin; PMB, polymyxin B; TGC, tigecycline.